Published in Br J Cancer on August 16, 2004
TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol (2013) 1.18
Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One (2014) 1.00
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG). BMC Immunol (2007) 0.99
Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol (2007) 0.92
Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha. BMC Immunol (2008) 0.89
Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol (2010) 0.87
High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder. Oncotarget (2015) 0.86
Toll-like receptors in urothelial cells--targets for cancer immunotherapy. Nat Rev Urol (2013) 0.85
Urinary tuberculosis is associated with the development of urothelial carcinoma but not renal cell carcinoma: a nationwide cohort study in Taiwan. Br J Cancer (2013) 0.85
Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol (2011) 0.84
Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response. Oncoimmunology (2012) 0.82
Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits. World J Urol (2007) 0.81
Shared occupational risks for transitional cell cancer of the bladder and renal pelvis among men and women in Sweden. Am J Ind Med (2008) 0.81
Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins. BMC Cancer (2007) 0.80
Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol (2006) 0.77
Prognostic value and efficacy valuation of postoperative intravesical instillation in primary urothelial carcinomas of upper urinary tract. Int J Clin Exp Med (2014) 0.76
Synergistic Cytotoxic Effects of Ganoderma lucidum and Bacillus Calmette Guérin on Premalignant Urothelial HUC-PC Cells and Its Regulation on Proinflammatory Cytokine Secretion. Evid Based Complement Alternat Med (2012) 0.75
Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model. PLoS One (2017) 0.75
Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment. Sci Rep (2016) 0.75
Granulomatous Prostatitis After Intravesical Bacillus Calmette-Guérin Instillation Therapy: A Potential Cause of Incidental F-18 FDG Uptake in the Prostate Gland on F-18 FDG PET/CT in Patients with Bladder Cancer. Nucl Med Mol Imaging (2015) 0.75
Expression of sialyl-Tn sugar antigen in bladder cancer cells affects response to Bacillus Calmette Guérin (BCG) and to oxidative damage. Oncotarget (2017) 0.75
The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol (2002) 2.63
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. BJU Int (2001) 1.56
Lipoprotein access to MHC class I presentation during infection of murine macrophages with live mycobacteria. J Immunol (2001) 1.52
A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer (2003) 1.50
Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest (1990) 1.42
Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Cancer Res (1987) 1.28
NK cells are essential for effective BCG immunotherapy. Int J Cancer (2001) 1.19
Express yourself or die: peptides, MHC molecules, and NK cells. Science (1995) 1.16
Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol (2003) 1.12
Evidence for human CD4+ T cells in the CD1-restricted repertoire: derivation of mycobacteria-reactive T cells from leprosy lesions. J Immunol (2000) 1.12
Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer (2000) 1.12
Cutting edge: major CD8 T cell response to live bacillus Calmette-Guérin is mediated by CD1 molecules. J Immunol (2003) 1.09
Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res (1991) 1.06
Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol (2000) 1.01
Bronchial epithelial cell-cytokine interactions in airway inflammation. J Investig Med (1995) 1.01
Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response. J Urol (2003) 0.96
The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer. Br J Cancer (1998) 0.92
Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol (2000) 0.92
Bacillus-Calmette-Guérin (BCG) and 3D tumors: an in vitro model for the study of adhesion and invasion. J Urol (1999) 0.92
Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res (1992) 0.91
Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG internalization into tumor cells. Int J Urol (2002) 0.90
Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res (1997) 0.90
BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Netw (1998) 0.90
Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol (2001) 0.89
Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol (1994) 0.89
Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol (1993) 0.82
Bacterial modulation of antigen processing and presentation. Microbes Infect (2000) 0.80
Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro. World J Urol (1994) 0.80
[Intravesical BCG-therapy: comparison of side effects of Connaught (Toronto) and Pasteur (Paris) strains]. Prog Urol (2000) 0.78
Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity? Urol Res (1992) 0.77
Theoretical and experimental evidence on the use of glycosaminoglycans in BCG-mediated immunotherapy of superficial bladder cancer. Semin Thromb Hemost (1994) 0.77
Intravesical bacillus calmette-guerin (BCG) as inducer of tumor-suppressing proteins p53 and p21 Waf1-Cip1 during treatment of superficial bladder cancer. J Urol (1999) 0.77